cse lvt

Levitee Labs Announces Azim Qazi as Head of Ecommerce and Consumer Packaged Goods

  • Azim Qazi, MBA, MCIPS, P.Log has over 20 years of management experience in supply chain management and business development
  • Mr. Qazi has a lengthy track record of optimizing processes to increase revenue and improve profit margins
  • Mr. Qazi will initially be responsible for the newly launched product lines of MONKE Nutraceuticals and the newly acquired Earth Circle Organics family of brands

Levitee Labs Inc. (the " Company " or " Levitee Labs ") (CSE: LVT), an integrative wellness company with a diversified portfolio of healthcare and wellness assets, is pleased to announce Azim Qazi, MBA, MCIPS, P.Log, as Head of Ecommerce and Consumer Packaged Goods (CPG).

In this role, Mr. Qazi, who has over 20 years of experience, will use his broad expertise in dynamic retail marketplaces, business development and supply chain management to oversee Company-wide CPG operations, beginning with the recently launched product lineups of MONKE Nutraceuticals, and Earth Circle Organics — which was acquired this month by Levitee for approximately $3.4 million — adding over 180 supplements and superfoods SKUs to the Company's portfolio of products. The Company has also launched the first two products from MONKE Nutraceuticals, mushroom-based adaptogenic supplements branded MONKE Mind and MONKE Body. Mr. Qazi will be responsible for leading accretive acquisitions for the Company within CPG, while managing omnichannel sales growth and optimization, identifying new opportunities, creating tools to increase visibility, developing future network simulations, and enhancing logistics through data, predictive capabilities, and process improvements.

"Levitee is an incredible opportunity, as it is truly at an inflection point with innovative products being introduced in the popular nutraceuticals and burgeoning mushroom markets," commented Azim Qazi. "The ecommerce space is constantly fluid, and I look forward to utilizing my skill set and understanding of vendor, supply chain and marketplace management with a premier marketing team to ensure the success of Levitee's brands today and in the future."

"Azim's background is impressive, starting with his early career mastering purchasing models at financial institutions in London to recently architecting a vendor-managed inventory framework in dropship ordering and enterprise resource planning system," said Pouya Farmand, Chief Executive Officer at Levitee Labs. "His knowledge, network, and leadership will prove invaluable across the full spectrum of our CPG businesses, from sourcing materials to reaching domestic and international consumers. He is a world-class warehousing and distribution specialist with a deep understanding of their impacts on P&L and meeting key performance indicators, and we're thrilled to have him join our team."

Prior to Levitee Labs, Mr. Qazi has worked with Cymax Stores and Cymax Group in multiple leadership positions including Category Manager at Cymax Stores during which he developed objectives and key results for key categories representing 50% of total revenue, managed 32 separate $1 million vendors, negotiated marketing promotions, analyzed PPC campaigns and grew category revenue by 39% while increasing margins by adding vendors and partnering with vendors on promotions and inventory allocation. He has also held the position of Marketplace Manager at Cymax Stores where he led a team of analysts, project managers, developers, and engineers with full P&L responsibility for the business unit, and improved marketplace revenue by 20% while increasing contribution margin by 4% through prioritizing high-margin items for marketing activity and eliminating poor-performing SKUs. He was also the Business Development Manager at Cymax Group where he oversaw the business unit with full P&L statement responsibility, established third-party logistics fulfillment housing network across North America, executed warehousing and distribution of 100 high-velocity home furnishing products, developed purchaser and supplier relationships while managing freight forwarders and customs brokers, and facilitated U.S. expansion for international manufacturers.

Mr. Qazi began his professional career as Procurement Executive, Prudential PLC where he generated approximately $6.6 million in cost savings through successful global reverse auctions. Subsequently, he served as Inventory & Logistics Manager, United Furniture Warehouse where he directed company-wide purchasing and logistics strategy, oversaw a $60 million annual budget, 87 stores, and 30 vendors across North America and Asia. He was also previously a Senior Purchaser at Coastal Contacts, Inc. where he managed 20,000 SKUs across 50 brands, directed COGS, replenishment, warehousing, and improved inventory turns in addition to holding the position of Inventory Manager at Spence Diamonds where he directed purchasing, logistics, and delivery of diamond jewelry and loose diamonds across 11 retail locations in US and Canada. Mr. Qazi optimized diamond inventory by analyzing 650,000 SKUs and implemented best practices that reduced inventory and improved cashflow. He was also the purchasing Manager at Genesis Nutrition where he established retail prices and margins, directed advertising and worked with a supply base of 50 vendors.

Mr. Qazi earned a BA in Printing & Publishing with Honors from Nottingham Trent University; MCIPS in Purchasing & Supply Chain Management from University of West London; and MBA in International Business from Hertfordshire University. He is a Certified Professional Logistician (P.Log) from Canadian Institute of Logistics; an Accredited Member of Chartered Institute of Purchasing and Supply; and Accredited Member of Canadian Institute of Logistics.

About Levitee Labs Inc.

Levitee Labs is establishing itself as a leader in the integrative wellness space. Through leveraging an M&A regimen that focuses on the centralization of complementary integrative wellness assets, Levitee Labs aims to transform mental health and addiction treatments through the integration of psychedelic medicines and therapies. The company's current portfolio of assets includes: MONKE Nutraceuticals, a company specialized in developing and distributing premium functional mushroom supplements sold via online portals; ACT Medical Centres, a group of five operating pain and addiction treatment clinics in Alberta; Block MD, the first telemedicine company in Alberta to receive provincial approval for telemedicine prescriptions in the addiction treatment space; three pharmacies operating in Alberta specialized in filling prescriptions for patients with substance abuse disorders, mental health conditions, and chronic pain; and Earth Circle Organics, a direct-to-consumer and wholesaler of supplements and superfood products with 180+ SKUs in its product lineup across three brands. Further information about Levitee Labs is available on its website at www.leviteelabs.com.

Forward-Looking Statements

This news release contains certain statements that may constitute forward-looking information under applicable securities laws. All statements, other than those of historical fact, which address activities, events, outcomes, results, developments, performance, or achievements that Levitee Labs anticipates or expects may or will occur in the future (in whole or in part) should be considered forward-looking information. Such information may involve, but is not limited to, statements respecting Levitee Labs' newly launched product lines of MONKE Nutraceuticals and Earth Circle Organics, Levitee Labs' business plans and proposed products, and the benefits derived from mushroom-infused products. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or statements formed in the future tense or indicating that certain actions, events or results "may", "could", "would", "might" or "will" (or other variations of the forgoing) be taken, occur, be achieved, or come to pass. These statements and other forward-looking information are based on assumptions made by Levitee Labs based on currently available competitive, financial and economic data and operating plans, strategies or beliefs as of the date of this news release as well as management's current expectations or beliefs regarding future growth, results of operations, future capital (including the amount, nature and sources of funding thereof) and expenditures. These assumptions may also be based on information obtained from third-party industry analysts and other third-party sources. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Levitee Labs as of the date such statements are made, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to risks associated with the following: Levitee Labs' limited history of operations; ability to secure additional financing; negative cash flow from operating activities since inception; regulatory requirements; changes in consumer preferences; supply of raw materials; reliance on a limited number of products; brand awareness; the ability to develop, market and produce new products; dependence on certain key senior managers; reliance on third parties for manufacturing and packaging; potential product liability claims and product recalls; and significant competition. For additional information regarding these risks, please see the risk factors identified and reported in Levitee Labs' public filings under its SEDAR profile at www.sedar.com. Any and all forward-looking information contained in this press release is expressly qualified by this cautionary statement. Readers are cautioned not to place undue reliance on forward-looking statements or information. The forward-looking information is made as of the date of this news release, and Levitee Labs assumes no obligation to publicly update or revise such forward-looking information, except as required by applicable securities laws. The CSE (operated by CNSX Markets Inc.) has neither approved nor disapproved of the contents of this press release and accepts no responsibility for the adequacy or accuracy hereof.

For further information about Levitee Labs Inc., please contact:

Media Contact:
media@leviteelabs.com

Investor and Corporate Communications:
ir@leviteelabs.com​


News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)
Levitee Labs

Levitee Labs

Overview

Shifting legal frameworks and regulatory changes have made psychedelic medicine one of the most promising solutions to mental health and addiction treatment in the modern age. Strong demand from therapists and patients for treatments involving psychedelic drugs like psilocybin has pushed the market to new heights, including a projected market size of over US$10.75 billion by 2027.

Globally, the market for functional mushrooms was US$5.8 billion in 2018 and could grow to a CAGR of 8.0 percent by 2024. Early-movers in the space can expect exceptional growth and economic success as the psychedelic space continues to gain traction as an increasingly positive remedy to limited responses to mental health, substance use and chronic pain crises around the world.

Keep reading...Show less

Transforming the Traditional Landscape of Mental Health, Addiction Treatment and Pain Management Treatment Across Multiple Verticals

Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto

Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto

lobe sciences ltd. (CSE: LOBE,OTC:LOBEF) (OTCQB: LOBEF) (FSE: LOBE.F) ("Lobe Sciences" or the "Company") a clinical stage biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs is pleased to announce its participation in the upcoming ArcStone-Kingswood Growth Summit in Toronto, taking place at the St. Regis Toronto on September 18, 2025. Dr. Frederick D Sancilio, CEO of lobe sciences ltd. will be presenting the company's recent milestones and future growth strategy.

The ArcStone-Kingswood Growth Summit will be hosting over 20 companies and a curated group of investors for a full day of pre-arranged, targeted 1-on-1 meetings, panel discussions and networking opportunities.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Dried mushrooms and capsules aligned on a light surface.

Psychedelics Market Update: H1 2025 in Review

The market for psychedelic drugs is emerging as a strategic investment opportunity in healthcare, with forecasts generally placing its value at around US$6.4 billion in 2025.

This burgeoning sector is set for robust, double-digit compound annual growth, significantly driven by North America, which is anticipated to account for approximately 45 to 50 percent of this market.

The first half of 2025 was characterized by clinical advancements and softening policy stances, furthering momentum and contributing to growing market interest.

Keep reading...Show less
Glowing mushrooms with colorful graphs in the background on a dark surface.

US Policy Momentum, Clinical Progress Fueling Psychedelics Market in 2025

When the US Food and Drug Administration (FDA) rejected Lykos Therapeutics’ new drug application for MDMA-assisted therapy last August, the initial disappointment cast a shadow over the psychedelics industry.

However, the sector is seeing a resurgence of optimism in 2025 on the back of various US developments.

“The psychedelic industry in 2025 will likely see significant advancements in clinical applications, particularly in treating PTSD, depression, and addiction, as research continues to validate their therapeutic potential,” Dr. Markus Ploesser, chief innovation officer at Open Mind Health, told Microdose in January.

Keep reading...Show less
AVECHO BIOTECHNOLOGY

Avecho and Sandoz enter Exclusive License and Development Agreement to Commercialise CBD for Insomnia in Australia

Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the “Company”) today announced it has signed an exclusive ten-year development and licensing agreement with Sandoz Group AG (“Sandoz”) for the commercial rights to Avecho’s Phase III cannabidiol (“CBD”) capsule for insomnia in Australia. Avecho retains the rights to commercialise the product in all other territories, with Sandoz granted a first right of refusal for these markets. Avecho’s CBD capsule aims to be the first pharmaceutical CBD product registered with the Therapeutic Goods Administration (“TGA”) as an over-the-counter medicine, which market forecasts predict could generate sales surpassing US$125M per annum in Australia2.

Keep reading...Show less

Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

Compass management will host a conference call at 8:00 am ET (1:00pm UK)

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Sunlit mushrooms growing on forest floor, backlit to show vibrant gills and earthy texture.

Psychedelics Market Forecast: Top Trends for Psychedelics in 2025

The psychedelics investment landscape enters 2025 on a complex path marked by both progress and setbacks.

While the US Food and Drug Association (FDA) continues to support research into the therapeutic potential of psychedelics, translating promising findings into approved treatments and accessible care is proving challenging.

This is evident in the recent legislative failures in Massachusetts and California, where initiatives aimed at expanding legal access to psychedelics were met with resistance. The FDA's August 2024 rejection of Lykos Therapeutics' midomafetamine for PTSD treatment underscores the rigorous standards required for regulatory approval.

Keep reading...Show less

Latest Press Releases

Related News

×